For example, stable disease (SD, a component of disease control response) that has been reported to achieved in a substantial percentage of cetuximab-treated KRAS-mutated CRC patients [62,63,64,65,66,67,68,69], can be only assessed during a long-term in vivo cetuximab treatment. The gene discussed is KRAS; the disease is colorectal carcinoma.